Hsu Po-Chih, Tsai Chung-Che, Lin Ya-Hsuan, Kuo Chan-Yen
Department of Dentistry, Taipei Tzu Chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
Institute of Oral Medicine and Materials, College of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Biomedicines. 2025 Jul 16;13(7):1745. doi: 10.3390/biomedicines13071745.
Oral squamous cell carcinoma (OSCC) is a prevalent and aggressive malignancy with poor prognosis, largely due to its high metastatic potential and resistance to conventional therapies. Recent advances in cancer biology have underscored the significance of regulated cell death pathways, including apoptosis, autophagic cell death (ACD), necroptosis, pyroptosis, and ferroptosis, in modulating tumor progression and therapeutic responses. This review provides the current insights into the molecular mechanisms underlying these cell death pathways and explores their therapeutic relevance in OSCC. Restoration of apoptosis using BH3 mimetics, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonists, and p53 reactivators shows promise for sensitizing OSCC cells to treatment. Autophagy plays context-dependent roles in cancer, acting as a tumor suppressor during early carcinogenesis by maintaining cellular homeostasis, and as a tumor promoter in established tumors by supporting cancer cell survival under stress. Targeting necroptosis and pyroptosis has emerged as a novel strategy for inducing cancer cell death, with compounds such as acetylshikonin and okanin demonstrating antitumor effects. Additionally, the induction of ferroptosis via lipid peroxidation and glutathione peroxidase 4 (GPX4) inhibition offers a promising avenue for overcoming drug resistance, with agents such as quercetin and trifluoperazine exhibiting preclinical success. Integration of these therapeutic approaches may enhance the OSCC treatment efficacy, reduce chemoresistance, and provide novel prognostic biomarkers for clinical management. Future studies should focus on optimizing combinatorial strategies that effectively leverage these pathways to improve OSCC patient outcomes.
口腔鳞状细胞癌(OSCC)是一种常见且侵袭性强的恶性肿瘤,预后较差,这主要归因于其高转移潜能和对传统疗法的耐药性。癌症生物学的最新进展凸显了包括凋亡、自噬性细胞死亡(ACD)、坏死性凋亡、炎性小体介导的细胞焦亡和铁死亡在内的程序性细胞死亡途径在调节肿瘤进展和治疗反应中的重要性。本综述提供了对这些细胞死亡途径潜在分子机制的当前见解,并探讨了它们在OSCC中的治疗相关性。使用BH3模拟物、肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)受体激动剂和p53激活剂恢复凋亡显示出使OSCC细胞对治疗敏感的前景。自噬在癌症中发挥着取决于背景的作用,在早期致癌过程中通过维持细胞稳态充当肿瘤抑制因子,而在已形成的肿瘤中通过在应激状态下支持癌细胞存活充当肿瘤促进因子。靶向坏死性凋亡和炎性小体介导的细胞焦亡已成为诱导癌细胞死亡的新策略,诸如乙酰紫草素和紫铆因等化合物已显示出抗肿瘤作用。此外,通过脂质过氧化和谷胱甘肽过氧化物酶4(GPX4)抑制诱导铁死亡为克服耐药性提供了一条有前景的途径,诸如槲皮素和三氟拉嗪等药物在临床前研究中已取得成功。整合这些治疗方法可能会提高OSCC的治疗效果,降低化疗耐药性,并为临床管理提供新的预后生物标志物。未来的研究应专注于优化联合策略,以有效利用这些途径来改善OSCC患者的预后。
Cancer Cell Int. 2025-6-24
Phytomedicine. 2024-7-25
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2018-2-6
Naunyn Schmiedebergs Arch Pharmacol. 2025-7-28
Front Immunol. 2025-4-3
Fundam Clin Pharmacol. 2025-6
Pharmaceuticals (Basel). 2025-2-26
Signal Transduct Target Ther. 2025-3-21
Cancer Metastasis Rev. 2025-2-15